Trial Profile
Phase III Randomized Multicenter Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms PSMA-SRT
- 17 Jul 2023 Planned End Date changed from 12 Jul 2024 to 12 Jul 2025.
- 17 Jul 2023 Planned primary completion date changed from 12 Jul 2023 to 12 Jul 2024.
- 07 Jun 2022 Results of a secondary endpoint analysis assessed the impact of PSMA PSMA PET/CT on the treatment plan presented at the 58th Annual Meeting of the American Society of Clinical Oncology